This episode is part of the Medical Innovation Series, Season 1 of The Hatch Podcast. Dive into the groundbreaking world of gene therapy with Chris Lucas, Co-Founder and Chief Scientific Officer of DNA Nanobots, on this episode of The Hatch Podcast. Learn how this biotech startup is leveraging DNA nanotechnology to transform drug delivery, reduce side effects, and make treatments more accessible. Discover their journey from Ohio State University labs to partnerships with leading pharmaceutical companies. Tune in for insights on the future of non-viral gene therapy, challenges in biotech innovation, and advice for aspiring entrepreneurs.

What You’ll Learn:

1. The Science Behind DNA Nanobots: How DNA is used to build nanoscale devices for targeted drug delivery.
2. Game-Changing Innovations: Why non-viral gene therapy is the future of medicine.
3. Overcoming Challenges: Lessons learned in transitioning a biotech startup from idea to execution.
4. Entrepreneurial Advice: Chris’s tips on simplifying your story and building impactful partnerships.

Quotes:

• "We consider ourselves the FedEx for pharmaceuticals, delivering medicine exactly where it needs to go."
• "Our nanotechnology approach is like a rocket ship—precisely targeted and consistent in design."
• "Simplify the story. Less is more when it comes to explaining innovation."

Sources and Links:

• Learn more about DNA Nanobots: www.dnanobots.com
• Hatch Fairhope: www.hatchfairhope.com
• Learn about Duchenne Muscular Dystrophy: Cure Duchenne
• Explore DNA nanotechnology: Research by Dr. Carlos Castro at Ohio State University.

Conclusion:

Chris Lucas and his team at DNA Nanobots are revolutionizing gene therapy with non-viral, targeted solutions. Their innovative approach promises to reduce costs, improve patient outcomes, and make gene therapy accessible for rare diseases and beyond. Stay tuned for updates as they continue to break new ground in biotech innovation.